Our results are consistent with other reports confirming that both NMO-IgG detected by tissue-based IIFA and AQP4 autoantibodies detected by cell-based IIFA are specific for NMOSD, and that their detection facilitates early distinction of NMOSD from CMS [5,8,10,15]. The gene discussed is AQP4; the disease is congenital myasthenic syndrome.